WO2009145489A3 - 세포투과성 엔도스타틴 재조합 단백질, 이를 코딩하는 폴리뉴클레오티드 및 이를 유효성분으로 함유하는 항암 조성물 - Google Patents
세포투과성 엔도스타틴 재조합 단백질, 이를 코딩하는 폴리뉴클레오티드 및 이를 유효성분으로 함유하는 항암 조성물 Download PDFInfo
- Publication number
- WO2009145489A3 WO2009145489A3 PCT/KR2009/001726 KR2009001726W WO2009145489A3 WO 2009145489 A3 WO2009145489 A3 WO 2009145489A3 KR 2009001726 W KR2009001726 W KR 2009001726W WO 2009145489 A3 WO2009145489 A3 WO 2009145489A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- cell
- recombinant protein
- same
- permeable
- cancer
- Prior art date
Links
- 102100031162 Collagen alpha-1(XVIII) chain Human genes 0.000 title abstract 8
- 108010079505 Endostatins Proteins 0.000 title abstract 8
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 title abstract 6
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 title abstract 6
- 230000001093 anti-cancer Effects 0.000 title abstract 4
- 102000040430 polynucleotide Human genes 0.000 title abstract 2
- 108091033319 polynucleotide Proteins 0.000 title abstract 2
- 239000002157 polynucleotide Substances 0.000 title abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 3
- 230000033115 angiogenesis Effects 0.000 abstract 2
- 230000015572 biosynthetic process Effects 0.000 abstract 2
- 230000002401 inhibitory effect Effects 0.000 abstract 2
- VEEGZPWAAPPXRB-BJMVGYQFSA-N (3e)-3-(1h-imidazol-5-ylmethylidene)-1h-indol-2-one Chemical compound O=C1NC2=CC=CC=C2\C1=C/C1=CN=CN1 VEEGZPWAAPPXRB-BJMVGYQFSA-N 0.000 abstract 1
- 229940121369 angiogenesis inhibitor Drugs 0.000 abstract 1
- 239000004037 angiogenesis inhibitor Substances 0.000 abstract 1
- 230000002491 angiogenic effect Effects 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 239000013604 expression vector Substances 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 229920002521 macromolecule Polymers 0.000 abstract 1
- 210000004088 microvessel Anatomy 0.000 abstract 1
- 230000005012 migration Effects 0.000 abstract 1
- 238000013508 migration Methods 0.000 abstract 1
- 230000035515 penetration Effects 0.000 abstract 1
- 239000008196 pharmacological composition Substances 0.000 abstract 1
- 230000035755 proliferation Effects 0.000 abstract 1
- 230000026683 transduction Effects 0.000 abstract 1
- 238000010361 transduction Methods 0.000 abstract 1
- 210000003556 vascular endothelial cell Anatomy 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Toxicology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US12/936,334 US8586544B2 (en) | 2008-04-04 | 2009-04-03 | Cell-permeable endostatin recombinant protein, a polynucleotide encoding the same, and an anti-cancer preparation containing the same as an active component |
EP09754954A EP2270055A4 (en) | 2008-04-04 | 2009-04-03 | CELLPERMEABLE RECOMBINANT ENDOSTATINE PROTEIN, POLYNUCLEOTIDE FOR ITS CODING AND ANTICIPATED PREPARATION WITH THE PROTEIN AS AN ACTIVE SUBSTANCE |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US4231208P | 2008-04-04 | 2008-04-04 | |
US61/042,312 | 2008-04-04 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2009145489A2 WO2009145489A2 (ko) | 2009-12-03 |
WO2009145489A3 true WO2009145489A3 (ko) | 2010-01-21 |
Family
ID=41377733
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/KR2009/001726 WO2009145489A2 (ko) | 2008-04-04 | 2009-04-03 | 세포투과성 엔도스타틴 재조합 단백질, 이를 코딩하는 폴리뉴클레오티드 및 이를 유효성분으로 함유하는 항암 조성물 |
Country Status (4)
Country | Link |
---|---|
US (1) | US8586544B2 (ko) |
EP (1) | EP2270055A4 (ko) |
KR (1) | KR101263424B1 (ko) |
WO (1) | WO2009145489A2 (ko) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10647968B2 (en) | 2011-09-09 | 2020-05-12 | Tsinghua University | Endostatin mutants with mutations at ATP binding sites |
WO2013115476A1 (ko) * | 2012-01-31 | 2013-08-08 | 국립암센터 | 검체 시료의 응집용 조성물, 이를 이용한 파라핀 블록의 제작방법 및 상기 파라핀 블록을 이용한 세포 마이크로어레이용 세포군집 표본의 제조방법 |
CN103992400B (zh) * | 2014-05-29 | 2017-01-04 | 江苏吴中医药集团有限公司苏州中凯生物制药厂 | 重组人血管内皮抑素的复性液及其制备、使用方法 |
CN104407153B (zh) * | 2014-12-03 | 2016-04-06 | 上海交通大学医学院附属上海儿童医学中心 | Map2k1作为诊断动脉导管闭合或开放的标志物 |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1999029855A1 (en) * | 1997-12-08 | 1999-06-17 | Beth Israel Deaconess Medical Center | Mutants of endostatin, 'em 1' having anti-angiogenic activity and methods of use thereof |
WO1999062944A2 (en) * | 1998-06-03 | 1999-12-09 | The Children's Medical Center Corporation | Protein oligomer compositions comprising endostatin protein and methods of using the same |
US20020123458A1 (en) * | 1995-10-23 | 2002-09-05 | O'reilly Michael S. | Endostatin protein and fragments thereof |
WO2003102187A1 (en) * | 2002-05-31 | 2003-12-11 | Scegen Pty Ltd | Self-coalescing or self-aggregating proteins derived from a membrane translocating sequence |
US7470667B2 (en) * | 2002-12-05 | 2008-12-30 | Medgenn (Hong Kong) Ltd | Methods of treating cancer using a modified endostatin protein |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2029273A1 (en) * | 1989-12-04 | 1991-06-05 | Christine L. Brakel | Modified nucleotide compounds |
US6346510B1 (en) * | 1995-10-23 | 2002-02-12 | The Children's Medical Center Corporation | Therapeutic antiangiogenic endostatin compositions |
US5854205A (en) * | 1995-10-23 | 1998-12-29 | The Children's Medical Center Corporation | Therapeutic antiangiogenic compositions and methods |
US6174861B1 (en) * | 1996-10-22 | 2001-01-16 | The Children's Medical Center Corporation | Methods of inhibiting angiogenesis via increasing in vivo concentrations of endostatin protein |
US6852691B1 (en) * | 1997-12-08 | 2005-02-08 | Beth Israel Deaconess Medical Center | Anti-angiogenic peptides and methods of use thereof |
US6797488B1 (en) * | 1997-12-08 | 2004-09-28 | Beth Israel Deaconess Medical Center | Methods of producing anti-angiogenic proteins |
EP1501861A4 (en) * | 2002-05-06 | 2007-06-20 | Univ Texas | TARGETED BINDING PROTEINS FOR THE ADMINISTRATION OF THERAPEUTIC OR DIAGNOSTIC REAGENTS |
US7078485B2 (en) * | 2002-12-05 | 2006-07-18 | Yantai Medgenn Ltd. | N-terminal modified recombinant human endostatin and its production |
AU2008211854C1 (en) | 2007-01-29 | 2014-01-23 | Procell Therapeutics Inc. | Novel macromolecule transduction domains and methods for identification and uses thereof |
-
2009
- 2009-04-03 EP EP09754954A patent/EP2270055A4/en not_active Withdrawn
- 2009-04-03 WO PCT/KR2009/001726 patent/WO2009145489A2/ko active Application Filing
- 2009-04-03 US US12/936,334 patent/US8586544B2/en active Active
- 2009-04-03 KR KR1020107022430A patent/KR101263424B1/ko active IP Right Grant
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20020123458A1 (en) * | 1995-10-23 | 2002-09-05 | O'reilly Michael S. | Endostatin protein and fragments thereof |
WO1999029855A1 (en) * | 1997-12-08 | 1999-06-17 | Beth Israel Deaconess Medical Center | Mutants of endostatin, 'em 1' having anti-angiogenic activity and methods of use thereof |
WO1999062944A2 (en) * | 1998-06-03 | 1999-12-09 | The Children's Medical Center Corporation | Protein oligomer compositions comprising endostatin protein and methods of using the same |
WO2003102187A1 (en) * | 2002-05-31 | 2003-12-11 | Scegen Pty Ltd | Self-coalescing or self-aggregating proteins derived from a membrane translocating sequence |
US7470667B2 (en) * | 2002-12-05 | 2008-12-30 | Medgenn (Hong Kong) Ltd | Methods of treating cancer using a modified endostatin protein |
Non-Patent Citations (1)
Title |
---|
See also references of EP2270055A4 * |
Also Published As
Publication number | Publication date |
---|---|
EP2270055A4 (en) | 2011-06-29 |
KR101263424B1 (ko) | 2013-05-14 |
KR20110013365A (ko) | 2011-02-09 |
EP2270055A2 (en) | 2011-01-05 |
WO2009145489A2 (ko) | 2009-12-03 |
US20110092441A1 (en) | 2011-04-21 |
US8586544B2 (en) | 2013-11-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2009145489A3 (ko) | 세포투과성 엔도스타틴 재조합 단백질, 이를 코딩하는 폴리뉴클레오티드 및 이를 유효성분으로 함유하는 항암 조성물 | |
Toton et al. | Beclin-1 and its role as a target for anticancer therapy | |
WO2009063970A1 (ja) | 抗gpr49抗体を用いる癌の診断および治療 | |
EP3778917A3 (en) | Multispecific antibodies, antibody analogs, compositions, and methods | |
WO2012083185A3 (en) | Peptide-based in vivo sirna delivery system | |
BR112014029099A2 (pt) | anticorpos anti-egfr e seu uso para inibir ou atenuar crescimento de tumor, bem como composição farmacêutica que o compreende | |
WO2009076580A3 (en) | Compositions and methods for the treatment and prevention of cardiovascular diseases | |
WO2010078517A3 (en) | Compositions and methods using sirna molecules and sirna cocktails for the treatment of breast cancer | |
EP3578568A3 (en) | Cxcr2 binding polypeptides | |
WO2012058592A3 (en) | Non-antagonistic egfr-binding molecules and immunoconjugates thereof | |
JO3291B1 (ar) | الأجسام المضادة لـ csf-1r | |
EA201071300A1 (ru) | Антитела к cxcr4 | |
WO2014117050A3 (en) | Modified mirna as a scaffold for shrna | |
WO2009151907A3 (en) | Compositions and methods for using cells to treat heart tissue | |
EP2592156A3 (en) | Gene expression markers of tumor resistance to HER2 inhibitor treatment | |
WO2013040093A3 (en) | Glucagon-like peptide-2 compositions and methods of making and using same | |
WO2011138328A3 (en) | Use of inhibitory molecules for the treatment of pulmonary hypertension | |
MX359258B (es) | Polipeptidos de enlace biparatopicos para cxcr2 y usos de los mismos. | |
WO2012112690A3 (en) | Targeting of therapeutic drugs and diagnostic agents employing collagen binding domains | |
WO2010056043A3 (en) | Cell-penetrating, sequence-specific and nucleic acid-hydrolyzing antibody, method for preparing the same and pharmaceutical composition comprising the same | |
WO2011081415A3 (ko) | c-Met의 발현을 저해하는 siRNA 및 이를 포함하는 항암 조성물 | |
EP2461681A4 (en) | USE OF MELANOCORTINS FOR TREATING DYSLIPIDEMIA | |
WO2010031749A9 (en) | Compositions and methods for detecting tlr3 | |
WO2011100330A3 (en) | Compositions and methods for preventing or treating a human parvovirus infection | |
WO2009069935A3 (en) | Pharmaceutical compositions and methods for delivering nucleic acids into cells |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 09754954 Country of ref document: EP Kind code of ref document: A2 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2009754954 Country of ref document: EP |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 20107022430 Country of ref document: KR Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 12936334 Country of ref document: US |